Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
Published: Jan 14, 2008
HOUSTON, Jan. 14, 2008 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced the commercial availability of THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets in Belgium and Luxembourg for the treatment of pulmonary arterial hypertension (PAH). Encysive received European Union (EU) marketing authorization for THELIN from the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist, and the first once-daily oral treatment commercially available for PAH patients in the EU.